DIGIT HF is a study about therapy of heart insufficiency, which is founded by the Bundesministerium für Bildung und Forschung (BMBF). In the study should be investigated if the drug Digoxin, which increases the contractility of the heart, can prolong the lives of patients with a particular form of heart failure and reduce their hospital stays. Digitoxin belongs to the group of digitalis componends that - originally derived from the foxglove - can be used in selected patients for the treatment of heart failure or cardiac arrhythmia.
The study participants suffering from advanced, chronic heart failure with reduced pumping capacity of the left ventricle, the so-called systolic heart failure. In Germany, up to two million people are affected. It is one of the most common causes of death and hospital admissions. In this heart failure, the heart can pump only reduced, which has a high level of suffering as consequence: The physical performance of the patients is very limited, they are quickly exhausted, they have arrhythmias, shortness of breath or they are even immobile.
In DIGIT study 40 clinical centers with 2.200 patients in total will be involved within 5 years. The main clinical center is the MHH.